1. Home
  2. RBCAA vs NTLA Comparison

RBCAA vs NTLA Comparison

Compare RBCAA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBCAA
  • NTLA
  • Stock Information
  • Founded
  • RBCAA 1974
  • NTLA 2014
  • Country
  • RBCAA United States
  • NTLA United States
  • Employees
  • RBCAA N/A
  • NTLA N/A
  • Industry
  • RBCAA Major Banks
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • RBCAA Finance
  • NTLA Health Care
  • Exchange
  • RBCAA Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • RBCAA 1.5B
  • NTLA 1.4B
  • IPO Year
  • RBCAA 1998
  • NTLA 2016
  • Fundamental
  • Price
  • RBCAA $76.06
  • NTLA $13.02
  • Analyst Decision
  • RBCAA
  • NTLA Buy
  • Analyst Count
  • RBCAA 0
  • NTLA 17
  • Target Price
  • RBCAA N/A
  • NTLA $56.63
  • AVG Volume (30 Days)
  • RBCAA 16.1K
  • NTLA 2.5M
  • Earning Date
  • RBCAA 01-24-2025
  • NTLA 11-07-2024
  • Dividend Yield
  • RBCAA 2.19%
  • NTLA N/A
  • EPS Growth
  • RBCAA 15.67
  • NTLA N/A
  • EPS
  • RBCAA 5.18
  • NTLA N/A
  • Revenue
  • RBCAA $324,440,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • RBCAA N/A
  • NTLA $52.90
  • Revenue Next Year
  • RBCAA $4.24
  • NTLA N/A
  • P/E Ratio
  • RBCAA $14.37
  • NTLA N/A
  • Revenue Growth
  • RBCAA 5.10
  • NTLA N/A
  • 52 Week Low
  • RBCAA $46.55
  • NTLA $12.47
  • 52 Week High
  • RBCAA $80.68
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • RBCAA 53.57
  • NTLA 37.06
  • Support Level
  • RBCAA $74.42
  • NTLA $12.47
  • Resistance Level
  • RBCAA $77.48
  • NTLA $13.79
  • Average True Range (ATR)
  • RBCAA 1.61
  • NTLA 0.80
  • MACD
  • RBCAA -0.35
  • NTLA -0.06
  • Stochastic Oscillator
  • RBCAA 51.57
  • NTLA 12.10

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through six reportable segments. It has traditional banking which generates the majority of revenue, warehouse, mortgage banking, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: